Management of Heart Failure, Durable Left Ventricular Assist Device, and Heart Transplant Patients in the COVID-19 Era

Research output: Contribution to journalReview articlepeer-review

Abstract

Our world is facing recurrent waves of coronavirus disease 2019 (COVID-19) with the emergence of more infectious strains of the novel coronavirus, SARS-CoV-2. Multiple studies have established that heart failure (HF) patients are at high risk of severe disease and poor outcomes with COVID-19. Management of COVID-19 in patients with HF, heart transplant, and those supported with durable left ventricular assist devices present an arduous challenge due to underlying complex health conditions and overlap of symptoms. Based on available data, this review outlines the management of this vulnerable patient population who either present with COVID-19 with preexisting HF or with de novo HF from COVID-19.

Original languageEnglish (US)
Pages (from-to)63-72
Number of pages10
JournalMethodist DeBakey cardiovascular journal
Volume17
Issue number5
DOIs
StatePublished - 2021

Keywords

  • COVID-19
  • heart failure
  • heart transplant
  • left ventricular assist device

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'Management of Heart Failure, Durable Left Ventricular Assist Device, and Heart Transplant Patients in the COVID-19 Era'. Together they form a unique fingerprint.

Cite this